Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report released on Saturday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Trading Down 2.6 %

Shares of EVOK stock opened at $4.59 on Friday. The firm has a fifty day simple moving average of $4.99 and a 200-day simple moving average of $5.33. The company has a market capitalization of $6.82 million, a PE ratio of -0.42 and a beta of 0.16. Evoke Pharma has a twelve month low of $3.54 and a twelve month high of $14.74.

Institutional Investors Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. bought a new stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma at the end of the most recent quarter.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.